The Single Photon Emission Computed Tomography (SPECT) Market is expected to register a CAGR of 5.7% during the forecast period. Single-photon Emission Computed Tomography (SPECT) is used in the evaluation of disease processes based on functional and metabolic information of organs and cells.
The most widely used SPECT systems are based on the Anger gamma camera, usually involving dual detectors that rotate around the patient. The application of hybrid equipment and fused techniques has increasing importance in the field of imaging diagnostics. One of the most significant advantages of these methods is the simultaneous use of several modalities, which can give data about the morphological, functional, and molecular changes of the different diseases at the same time.
According to the World Health Organization (WHO), in the year 2018, worldwide estimated 18.1 million new cases of cancer and approximately 9.6 million deaths. In addition, one in 5 men and one in 6 women globally develop cancer during their lifetime, and one in 8 men and one in 11 women die from the disease.
The integration of X-ray computed tomography (CT) into SPECT has recently emerged as an essential diagnostic tool in medical imaging, where anatomical details may delineate functional and metabolic information.
Furthermore, there is an increasing trend of dual-modality systems and organ-specific systems, to enhance the diagnostic capability of the equipment. In the past several years, there has been growing utilization of PET/CT, owing to the fact that functional and morphologic correlative images produced by this methodology improve diagnostic accuracy, and it is one of the factors that can impede the growth of the SPECT equipment market. Thus, owing to all factors mentioned above, the market is expected to witness satisfactory growth over the forecast period.
Key Market Trends
Gallium-67 Segment is Expected to Witness Highest CAGR Over the Forecast Period in the Single Photon Emission Computed Tomography (SPECT) Market
Gallium-67 radioisotope is used for diagnosing inflammation, both acute and chronic infection, and tumours, such as Hodgkin’s disease, lymphoma (except for lymphocytic), hepatoma, and bronchogenic carcinoma. Mostly, it is used as a bone imaging agent.
Gallium-67 is of a gold standard for tumour diagnosis and staging. Hybrid imaging using Ga-67 SPECT/CT enables the correct localization of lymphoma lesions. Ga-67 is a commonly used agent for the imaging of inflammation, because of its ability to accumulate non-specifically in inflamed areas as a metal-transferrin complex, followed by further binding to transferrin receptors. Some of the market players, which provide Gallium Citrate GA-67 are Lantheus Medical Imaging and Mallinckrodt Nuclear.
According to the International Agency for Research on Cancer (IARC), by the year 2040, it is estimated that new cases of cancer to grow to 27.5 million. In addition, the global cancer burden is anticipated to increase by 70% in the next 20 years.
Thus, owing to the rising prevalence of various bone disorders, cancers and benefits associated with Gallium-67, the market is expected to witness a high growth rate over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
The SPECT market in the United States is growing propelled by the advancements in technology, including hybrid imaging, the introduction of new radiopharmaceuticals for diagnosis, and the development of molecular imaging. Technetium 99m (TC-99m) is the most widely used imaging agent, due to its versatility. According to the American Cancer Society, estimated that in 2020 there will be about 1.8 million new cancer cases diagnosed and approximately 606,520 cancer deaths in the United States.
Recently, in March 2018, Canadian Nuclear Laboratory (CNL), Chalk River, discontinued the function of the nuclear reactor that processes molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m). With the exit of this company from using Tc-99m, there are only six suppliers left in the global market which are from North America region only. Therefore, North America is gaining attraction in the global market for Tc-99m. Hence, it is expected that this region will be dominating the market studied.
The Single Photon Emission Computed Tomography (SPECT) Market is consolidated competitive and consists mostly of global players such as Koninklijke Philips NV, Siemens AG, GE Healthcare (GE Company), etc. With the growing burden of chronic diseases across the globe and the rising significance of SPECT in various diseases, few companies are expected to enter the market studied.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support